Cellular events and biomarkers of wound healing

Jumaat Mohd Yussof Shah, Effat Omar, Dinker R Pai, Suneet Sood, Jumaat Mohd Yussof Shah, Effat Omar, Dinker R Pai, Suneet Sood

Abstract

Researchers have identified several of the cellular events associated with wound healing. Platelets, neutrophils, macrophages, and fibroblasts primarily contribute to the process. They release cytokines including interleukins (ILs) and TNF-α, and growth factors, of which platelet-derived growth factor (PDGF) is perhaps the most important. The cytokines and growth factors manipulate the inflammatory phase of healing. Cytokines are chemotactic for white cells and fibroblasts, while the growth factors initiate fibroblast and keratinocyte proliferation. Inflammation is followed by the proliferation of fibroblasts, which lay down the extracellular matrix. Simultaneously, various white cells and other connective tissue cells release both the matrix metalloproteinases (MMPs) and the tissue inhibitors of these metalloproteinases (TIMPs). MMPs remove damaged structural proteins such as collagen, while the fibroblasts lay down fresh extracellular matrix proteins. Fluid collected from acute, healing wounds contains growth factors, and stimulates fibroblast proliferation, but fluid collected from chronic, nonhealing wounds does not. Fibroblasts from chronic wounds do not respond to chronic wound fluid, probably because the fibroblasts of these wounds have lost the receptors that respond to cytokines and growth factors. Nonhealing wounds contain high levels of IL1, IL6, and MMPs, and an abnormally high MMP/TIMP ratio. Clinical examination of wounds inconsistently predicts which wounds will heal when procedures like secondary closure are planned. Surgeons therefore hope that these chemicals can be used as biomarkers of wounds which have impaired ability to heal. There is also evidence that the application of growth factors like PDGF will help the healing of chronic, nonhealing wounds.

Keywords: Cytokines; growth factors; matrix metalloproteinases; platelet-derived growth factor; wound healing.

Conflict of interest statement

Conflict of Interest: None declared

References

    1. Buchanan EP, Lorenz HP. Wound healing, including fetal skin healing. In: Bahman G, Eriksson E, Persing JA, editors. Plastic Surgery: Indications and Practice. Elsevier; 2009. pp. 9–26.
    1. Chin GC, Diegelmann RF, Schultz GS. Cellular and molecular regulation of wound healing. In: Falabella AF, Kirsner RS, editors. Wound Healing. Boca Raton: Taylor & Francis Group; 2005. pp. 17–37.
    1. Antoniades HN, Scher CD, Stiles CD. Purification of human platelet-derived growth factor. Proc Natl Acad Sci U S A. 1979;76:1809–13.
    1. Kumar V, Abbas AA, Fausto N, editors. Robbins and Cotran's Pathologic Basis of Disease. 7th edition. Philadelphia: Elsevier; 2005. Tissue renewal and repair: regeneration, healing, and fibrosis; pp. 87–118.
    1. LeBlanc S, Arabzadeh A, Benlolo S, Breton V, Turbide C, Beauchemin N, et al. CEACAM1 deficiency delays important wound healing processes. Wound Repair Regen. 2011;19:745–52.
    1. Diegelmann RF, Evans MC. Wound healing: An overview of acute, fibrotic and delayed healing. Front Biosci. 2004;9:283–9.
    1. Li J, Kirsner RS. Extracellular matrix and wound healing. In: Falabella AF, Kirsner RS, editors. Wound Healing. Boca Raton: Taylor & Francis Group; 2005. pp. 39–48.
    1. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP. FASEB J. 1999;13:1774–86.
    1. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002;160:2009–18.
    1. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009;17:153–62.
    1. Rumalla VK, Borah GL. Cytokines, growth factors, and plastic surgery. Plast Reconstr Surg. 2001;108:719–33.
    1. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009;153:347–58.
    1. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol. 1991;25:1054–8.
    1. Mendez MV, Raffetto JD, Phillips T, Menzoian JO, Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg. 1999;30:734–43.
    1. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen. 1993;1:181–6.
    1. Agren MS, Eaglstein WH, Ferguson MW, Harding KG, Moore K, Saarialho-Kere UK, et al. Causes and effects of the chronic inflammation in venous leg ulcers. Acta Derm Venereol Suppl (Stockh) 2000;210:3–17.
    1. Mendez MV, Stanley A, Park HY, Shon K, Phillips T, Menzoian JO. Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg. 1998;28:876–83.
    1. Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD, et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol. 2002;81:153–60.
    1. Cowin AJ, Hatzirodos N, Holding CA, Dunaiski V, Harries RH, Rayner TE, et al. Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers. J Invest Dermatol. 2001;117:1282–9.
    1. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000;8:13–25.
    1. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol. 1996;107:743–8.
    1. Snyder RJ, Driver V, Fife CE, Lantis J, Peirce B, Serena T, et al. Using a diagnostic tool to identify elevated protease activity levels in chronic and stalled wounds: A consensus panel discussion. Ostomy Wound Manage. 2011;57:36–46.
    1. Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002;10:26–37.
    1. White RJ, Cutting KF. Critical colonization--the concept under scrutiny. Ostomy Wound Manage. 2006;52:50–6.
    1. Hahm G, Glaser JJ, Elster EA. Biomarkers to predict wound healing: The future of complex war wound management. Plast Reconstr Surg. 2011;127(Suppl 1):21S–6S.
    1. Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg. 2009;49:1013–20.
    1. Gohel MS, Windhaber RA, Tarlton JF, Whyman MR, Poskitt KR. The relationship between cytokine concentrations and wound healing in chronic venous ulceration. J Vasc Surg. 2008;48:1272–7.
    1. Harris IR, Yee KC, Walters CE, Cunliffe WJ, Kearney JN, Wood EJ, et al. Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exp Dermatol. 1995;4:342–9.
    1. Forsberg JA, Elster EA, Andersen RC, Nylen E, Brown TS, Rose MW, et al. Correlation of procalcitonin and cytokine expression with dehiscence of wartime extremity wounds. J Bone Joint Surg Am. 2008;90:580–8.
    1. Utz ER, Elster EA, Tadaki DK, Gage F, Perdue PW, Forsberg JA, et al. Metalloproteinase expression is associated with traumatic wound failure. J Surg Res. 2010;159:633–9.
    1. Asada M, Nakagami G, Minematsu T, Nagase T, Akase T, Huang L, et al. Novel biomarkers for the detection of wound infection by wound fluid RT-PCR in rats. Exp Dermatol. 2012;21:118–22.
    1. Butte AJ, Dzau VJ, Glueck SB. Further defining housekeeping, or “maintenance,” genes Focus on “A compendium of gene expression in normal human tissues”. Physiol Genomics. 2001;7:95–6.
    1. Moor AN, Vachon DJ, Gould LJ. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Repair Regen. 2009;17:832–9.
    1. Thomas AN, Riazanskaia S, Cheung W, Xu Y, Goodacre R, Thomas CL, et al. Novel noninvasive identification of biomarkers by analytical profiling of chronic wounds using volatile organic compounds. Wound Repair Regen. 2010;18:391–400.
    1. Robson MC. Wound infection. A failure of wound healing caused by an imbalance of bacteria. Surg Clin North Am. 1997;77:637–50.
    1. Robson MC, Stenberg BD, Heggers JP. Wound healing alterations caused by infection. Clin Plast Surg. 1990;17:485–92.
    1. Robson MC. Wound healing and wound closure. In: Heggers JP, Robson MC, editors. Quantitative bacteriology: Its role in the armamentarium of the surgeon. Boca Raton FL: CRC Press; 1991. –43.pp. 54
    1. Gope R. The effect of epidermal growth factor & platelet-derived growth factors on wound healing process. Indian J Med Res. 2002;116:201–6.
    1. Victor-Vega C, Desai A, Montesinos MC, Cronstein BN. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel) Inflammation. 2002;26:19–24.
    1. Montesinos MC, Shaw JP, Yee H, Shamamian P, Cronstein BN. Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol. 2004;164:1887–92.
    1. Macedo L, Pinhal-Enfield G, Alshits V, Elson G, Cronstein BN, Leibovich SJ. Wound healing is impaired in MyD88-deficient mice: A role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol. 2007;171:1774–88.
    1. Mogford JE, Tawil B, Jia S, Mustoe TA. Fibrin sealant combined with fibroblasts and platelet-derived growth factor enhance wound healing in excisional wounds. Wound Repair Regen. 2009;17:405–10.
    1. Lariviere B, Rouleau M, Picard S, Beaulieu AD. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects. Wound Repair Regen. 2003;11:79–89.
    1. Cheng B, Liu HW, Fu XB, Sun TZ, Sheng ZY. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci. 2007;45:193–201.
    1. Engrav LH, Richey KJ, Kao CC, Murray MJ. Topical growth factors and wound contraction in the rat: Part II.Platelet-derived growth factor and wound contraction in normal and steroid-impaired rats. Ann Plast Surg. 1989;23:245–8.
    1. Uhl E, Rosken F, Sirsjo A, Messmer K. Influence of platelet-derived growth factor on microcirculation during normal and impaired wound healing. Wound Repair Regen. 2003;11:361–7.
    1. Mustoe TA, Purdy J, Gramates P, Deuel TF, Thomason A, Pierce GF. Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB. Am J Surg. 1989;158:345–50.
    1. Blume P, Driver VR, Tallis AJ, Kirsner RS, Kroeker R, Payne WG, et al. Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers. Wound Repair Regen. 2011;19:302–8.
    1. Liechty KW, Nesbit M, Herlyn M, Radu A, Adzick NS, Crombleholme TM. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol. 1999;113:375–83.
    1. Breitbart AS, Laser J, Parrett B, Porti D, Grant RT, Grande DA, et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg. 2003;51:409–14.
    1. Chan RK, Liu PH, Pietramaggiori G, Ibrahim SI, Hechtman HB, Orgill DP. Effect of recombinant platelet-derived growth factor (Regranex) on wound closure in genetically diabetic mice. J Burn Care Res. 2006;27:202–5.
    1. Karr BP, Bubak PJ, Sprugel KH, Pavlin EG, Engrav LH. Platelet-derived growth factor and wound contraction in the rat. J Surg Res. 1995;59:739–42.
    1. Hammacher A, Mellstrom K, Heldin CH, Westermark B. Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. EMBO J. 1989;8:2489–95.
    1. Watts SA. Platelet-derived growth factor for foot ulcerations. An effective adjunct to good wound care. Adv Nurse Pract. 2001;9:60–3.
    1. Ehrlich HP, Freedman BM. Topical platelet-derived growth factor in patients enhances wound closure in the absence of wound contraction. Cytokines Cell Mol Ther. 2002;7:85–90.
    1. Fernandez-Montequin JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galan-Naranjo K, Ramirez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: Treatment up to complete wound closure. Int Wound J. 2009;6:67–72.
    1. Kurtz MP, Svensson E, Heimann TM. Use of platelet-derived growth factor for delayed perineal wound healing in patients with inflammatory bowel disease: A case series. Ostomy Wound Manage. 2011;57:24–31.
    1. Shackelford DP, Fackler E, Hoffman MK, Atkinson S. Use of topical recombinant human platelet-derived growth factor BB in abdominal wound separation. Am J Obstet Gynecol. 2002;186:701–4.
    1. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: A phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen. 1999;7:141–7.
    1. Ono I, Akasaka Y, Kikuchi R, Sakemoto A, Kamiya T, Yamashita T, et al. Basic fibroblast growth factor reduces scar formation in acute incisional wounds. Wound Repair Regen. 2007;15:617–23.
    1. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care. 1995;18:64–9.
    1. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26:1856–61.
    1. Mohan VK. Recombinant human epidermal growth factor (REGEN-D 150): Effect on healing of diabetic foot ulcers. Diabetes Res Clin Pract. 2007;78:405–11.
    1. Ginsburg GS, Willard HF. Genomic and personalized medicine: Foundations and applications. Transl Res. 2009;154:277–87.
    1. Jones J, Libermann TA. Genomics of renal cell cancer: The biology behind and the therapy ahead. Clin Cancer Res. 2007;13:685s–92s.
    1. Auffray C, Chen Z, Hood L. Systems medicine: The future of medical genomics and healthcare. Genome Med. 2009;1:2.
    1. Hawksworth JS, Stojadinovic A, Gage FA, Tadaki DK, Perdue PW, Forsberg J, et al. Inflammatory biomarkers in combat wound healing. Ann Surg. 2009;250:1002–7.
    1. Lantis JC, 2nd, Boone D, Gendics C, Todd G. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care. 2009;22:167–71.
    1. Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res. 2009;9:115.
    1. Pomahac B, Hirsch T, Eriksson E. Wound management. In: Bahman G, Eriksson E, Persing JA, editors. Plastic Surgery: Indications and Practice. Elsevier; 2009. pp. 27–36.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren